May 17,2023

Flatiron adds service with 'data empathy' for oncology trials

Flatiron Health debuted its latest offering of its real-world evidence (RWE) platform to include data and end-to-end services focused on growing needs in the arena of oncology clinical trials. The additions by Flatiron provide a one-stop-shop for oncology real-world data by giving customers more flexibility in the way they engage with the platform to deliver oncology evidence solutions tailored to their particular needs, the company said in a May 15 press release.

PRODUCT

#rwe

#rwd

View Analyst & Ambassador Comments
Go to original news
May 14,2023

Dave, the World’s First Real-time Conversational AI Oncology Mentor

Belong.Life, a leading global provider of high-engagement patient communities and care platforms, today announced the launch of Dave, the world’s first conversational AI oncology mentor for cancer patients. With the mission of improving access to quality cancer care for patients worldwide, Dave brings a new level of support to cancer patients and their families. Dave is designed to engage and continuously educate, support and guide cancer patients and caregivers on their clinical journey, providing support and personalized information. Conversational AI platform created and trained using deep learning on billions of unique data points and anonymized real world patient journey information accumulated over seven years on Belong’s platform.

PRODUCT

#mobile app

#chatbot

View Analyst & Ambassador Comments
Go to original news
May 08,2023

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated data related to vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress. Four posters will be presented during the poster session at the annual congress, which will be held from May 11-13, 2023, in Berlin, Germany.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 09,2023

Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets

Under the agreement, Thermo Fisher will identify local labs that will be using the company's NGS technology and ensure they have the necessary infrastructure, trained staff, and quality control measures to meet industry standards for NGS testing services for breast and lung cancer. Pfizer will explore ways to enable affordable patient access for NGS testing for these types of cancer and work to raise healthcare provider awareness regarding the benefits of advanced testing. The two companies will continue to evaluate opportunities to expand geographically and to expand testing for other types of cancer.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 10,2023

Mercurius Health equips Robert Janker Klinik with integrated oncology solutions from Philips and Elekta

Royal Philips, radiation therapy leader Elekta, and oncology service provider Mercurius Health today announced the signing of a 3-year agreement under which Philips and Elekta will install state-of-the-art diagnostic and therapeutic oncology equipment and associated informatics solutions at Mercurius Health’s newly-acquired Robert Janker Klinik cancer center in Bonn, Germany. The agreement has been enabled by the strategic partnership between Philips and Elekta to advance comprehensive personalized cancer care through the deployment of precision oncology solutions. “The combination of Philips’ diagnostic imaging and oncology informatics solutions, and Elekta’s radiation therapy solutions means we will be able to offer our patients state-of-the-art therapy for tumors such as prostate and liver cancer that are currently difficult to treat, improving clinical outcomes,” said Prof. Dr. Michael Pinkawa, Radiation Oncologist and Head of Radiotherapy at Robert Janker Klinik.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 12,2023

Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer

Veracyte announced that new data show the use of the Prosigna Breast Cancer Assay altered treatment decisions for patients with early-stage breast cancer, including significantly reducing the use of chemotherapy among those with clinically high-risk disease. The findings are from EMIT, a prospective, multi-year, population-based study in Norway that is investigating the impact of molecular testing – specifically, the Prosigna test – on breast cancer care and outcomes. For the study, researchers evaluated data for 2,164 women in Norway with early-stage (node-negative) breast cancer, recording physicians’ treatment decisions for these patients before and after a Prosigna test result. Prior to Prosigna results, physicians directed 27% to no systemic treatment (low-risk patients), 38% to endocrine therapy only (intermediate-risk patients) and 35% to chemotherapy followed by endocrine therapy (high-risk patients). After Prosigna test results, these treatment decisions changed to 25%, 51% and 24%, respectively. Notably, for patients assigned to chemotherapy prior to Prosigna results, 45% were de-escalated to endocrine therapy following Prosigna results.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
May 08,2023

Cankado Comments on the Removal of Its App from the DiGA List in Germany

Cankado released a pulic announcement that the BfArM has initially removed PRO-React Onco from the DiGA directory for purely formal reasons. A new entry in the DiGA directory should take place as soon as possible. In 2021, based on the "PreCycle" study, which was still ongoing at the time, Cankado initially applied for the provisional inclusion of PRO-React Onco in the DiGA directory. For final inclusion in the DiGA directory, the evidence-bearing study must be fully completed. Cankado said that it was not foreseeable that the PreCycle study would be completed within the trial period, and the AIPEC study was designed and submitted as a trial study. In the application for the final inclusion of PRO-React Onco in the DiGA directory in 2023, the start-up decided to submit the positive care effect based on the final results of the PreCycle study due to the very good results. However, since they named the AIPEC study as the evidence-bearing study in our original application from 2021, the BfArM insisted that the positive healthcare effects should only be derived from this study. Cankado commented that the company will be pursuing re-applicaiton and final inclusion of PRO-React Onco based on the data from the PreCycle study.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 08,2023

AI Predicts Future Pancreatic Cancer

The findings, published May 8 in Nature Medicine, suggest that AI-based population screening could be valuable in finding those at elevated risk for the disease and could expedite the diagnosis of a condition found all too often at advanced stages when treatment is less effective and outcomes are dismal, the researchers said. Currently, there are no population-based tools to screen broadly for pancreatic cancer. Those with a family history and certain genetic mutations that predispose them to pancreatic cancer are screened in a targeted fashion. But such targeted screenings can miss other cases that fall outside of those categories, the researchers said. In the new study, the AI algorithm was trained on two separate data sets totaling 9 million patient records from Denmark and the United States. The researchers "asked" the AI model to look for telltale signs based on the data contained in the records. Based on combinations of disease codes and the timing of their occurrence, the model was able to predict which patients are likely to develop pancreatic cancer in the future.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 10,2023

3 New CancerIQ Offerings Announced at City of Hope 2023: Making Precision Prevention Actionable and Equitable at Scale

Feyi Ayodele, Chief Executive Officer and Co-Founder, CancerIQ announced 3 new offerings during her featured session, "Making Precision Prevention Actionable and Equitable at Scale.” CancerIQ is taking the mission to support genetics professionals one step further with the Case Sharing Network — a functionality within the CancerIQ platform allowing users to share comprehensive, de-identified data and collaborate with other genetics specialists and leaders in preventive oncology. Secondly, CancerIQ announced more robust research partnerships through two main tracks — either on the actual data behind the network or by actually using CancerIQ platform to capture patient data and run their testing and care plans. Thirdly, the Company announced new partnerships to ensure patients are actually adhering to recommendations. CancerIQ announced the partnership with content creators like DenaDNA and building a team of advocates who are in tune with what patients need to feel empowered rather than overwhelmed by their options.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
May 04,2023

OncoHost Licenses Biosensing Technology From BGN Technologies to Predict Immunotherapy Response

OncoHost said it has licensed AI technology for predicting anti-PD-1 therapy response from BGN Technolgies, the technology transfer company of Ben-Gurion University of the Negev in Israel. The immuno-checkpoint Artificial Reporter (IcAR) biosensing techology was developed by BGU researchers to measure binding of PD-L1 and PD-L2 to PD-1. Bheer-shva, Israel-based BGN Technologies is hoping that IcAR will be able to identify accurately the between 20-40% of cancer patients who are likely to benefit from immune checkpoint inhibitors and do so better than existing PD_l1 biomarker tests, the use of which are presently limiter to specific cancer types.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY